LONGEVA.

BMP-7: adverse events and evidence limits

Friedlaender and colleagues studied BMP-7 as a collagen-carried rhOP-1 implant for tibial nonunion, not systemic injections. Implant and bone-autograft groups each included 61 patients, followed for up to 24 months. [1]

All patients experienced postoperative adverse events; serious events occurred in 44% of each group, and investigators did not attribute them to the grafts. These are not BMP-7-caused reaction rates or a safety assessment of another formulation or route. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Postoperative adverse events overallPatients with tibial nonunion: 61 in the collagen-carried rhOP-1 implant group and 61 in the bone-autograft group, followed for up to 24 monthsOccurred in all patients (100% — very common on the pharmacy scale, ≥10%); these are postoperative events, not BMP-7-caused reaction rates[1]
Serious adverse eventsThe same patient groups44% of each group (very common, ≥10%); investigators did not attribute them to the grafts[1]

References

  1. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. (2001). Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions https://doi.org/10.2106/00004623-200100002-00010.